Understanding and Exploiting the Effect of Tuberculosis Antimicrobials on Host Mitochondrial Function and Bioenergetics
Open Access
- 15 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
Abstract
Almost 140 years after its discovery, tuberculosis remains the leading infectious cause of death globally. For half a century, patients with drug-sensitive and drug-resistant tuberculosis have undergone long, arduous, and complex treatment processes with several antimicrobials that primarily function through direct bactericidal activity. Long-term utilization of these antimicrobials has been well-characterized and associated with numerous toxic side-effects. With the prevalence of drug-resistant strains on the rise and new therapies for tuberculosis urgently required, a more thorough understanding of these antimicrobials is a necessity. In order to progress from the “one size fits all” treatment approach, understanding how these antimicrobials affect mitochondrial function and bioenergetics may provide further insight into how these drugs affect the overall functions of host immune cells during tuberculosis infection. Such insights may help to inform future studies, instigate discussion, and help toward establishing personalized approaches to using such antimicrobials which could help to pave the way for more tailored treatment regimens. While recent research has highlighted the important role mitochondria and bioenergetics play in infected host cells, only a small number of studies have examined how these antimicrobials affect mitochondrial function and immunometabolic processes within these immune cells. This short review highlights how these antimicrobials affect key elements of mitochondrial function, leading to further discussion on how they affect bioenergetic processes, such as glycolysis and oxidative phosphorylation, and how antimicrobial-induced alterations in these processes can be linked to downstream changes in inflammation, autophagy, and altered bactericidal activity.Keywords
Funding Information
- Science Foundation Ireland (18/TIDA/6026)
This publication has 60 references indexed in Scilit:
- Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse MRSA Pneumonia ModelPLOS ONE, 2013
- Effect of Rifampin on Production of Inflammatory Mediators in HepG2 Liver Epithelial CellsAntimicrobial Agents and Chemotherapy, 2011
- Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic VariabilityThe Journal of Infectious Diseases, 2011
- Size and Usage Patterns of Private TB Drug Markets in the High Burden CountriesPLOS ONE, 2011
- Immunomodulation with Recombinant Interferon-γ1b in Pulmonary TuberculosisPLOS ONE, 2009
- Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TBEuropean Respiratory Journal, 2009
- Influence on Mitochondria and Cytotoxicity of Different Antibiotics Administered in High Concentrations on Primary Human Osteoblasts and Cell LinesAntimicrobial Agents and Chemotherapy, 2007
- Calcium Signals Are Affected by Ciprofloxacin as a Consequence of Reduction of Mitochondrial DNA Content in Jurkat CellsAntimicrobial Agents and Chemotherapy, 2006
- Rifampicin Inhibition of Protein Synthesis in Mammalian CellsScience, 1978
- The effect of rifampicin on mitochondrial RNA polymerase from rat liverFEBS Letters, 1970